LONN Lonza Group AG

792.19USD667.60 CHF · SWX+0.15%Mkt Cap: 55.28B USDP/E: 44.20

Lonza Group AG, together with its subsidiaries, operates as a contract development and manufacturing organization for pharma and biotech companies in Europe, North and Central America, Latin America, Asia, Australia, New…

Institutional holders13 on file

Key Statistics

Company
Market Cap55.28B USD
Enterprise Value59.63B USD
Revenue (TTM)8.15B USD
Gross Profit2.74B USD
Net Income (TTM)-326.32M USD
Revenue/Share116.68 USD
Last Price792.19 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees20.1K
CountryCH
SectorHealthcare
IndustryDiagnostics & Research
ISINCH0013841017
Valuation
P/E (Trailing)44.20
P/E (Forward)29.70
PEG1.20
EV/EBITDA21.03
EV/Revenue7.31
P/S6.78
P/B5.73
EPS (TTM)17.91 USD
EPS (Forward)26.65 USD
52W Range
539.4496% of range801.69
52W High801.69 USD
52W Low539.44 USD
Profitability
Gross Margin35.35%
Oper. Margin23.49%
EBITDA Margin34.78%
Profit Margin-4.21%
ROE-3.48%
ROA-1.54%
ROIC9.51%
ROCE9.51%
Growth
Revenue Growth11.20%
Earnings Growth39.20%
Cash Flow & Leverage
Operating CF1.37B USD
CapEx (TTM)1.63B USD
FCF Margin-22.81%
FCF Yield-3.36%
Net Debt4.37B USD
Net Debt/EBITDA1.54
Net Debt/FCF—
Balance Sheet
Debt/Equity0.57
Current Ratio1.66
Quick Ratio0.59
Book Value/Sh138.09 USD
Cash/Share8.28 USD
Dividends
Fwd Div Rate5.93 USD
Trail. Div Rate5.93 USD
Div. Yield0.75%
5Y Avg Yield0.68%
Payout Ratio32.28%
Ex-Div DateMay 12, 2026
Pay DateMay 15, 2025
Analyst Consensus
Rating1.5 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)853.96 USD
Upside (mean)+7.8%
Target Range652.65 USD – 1052.54 USD
652.65+7.8% to mean1052.54
# Analysts23
Ownership
Shares Out.69.84M
Float69.74M
Insiders0.09%
Institutions58.54%
Technical
SMA 50715.94 (+10.7%)
SMA 200646.67 (+22.5%)
Beta0.80
S&P 52W Chg12.00%
Avg Vol (30d)141.95K
Avg Vol (10d)130.56K
Technical Indicators
RSI (14)69.1
MACD17.1120
MACD Signal19.0451
MACD Hist.-1.9332
BB Upper810.16 USD
BB Middle777.11 USD
BB Lower744.06 USD
BB Width8.50%
ATR (14)12.79 USD
Vol Ratio (20d)0.84x

About Lonza Group (SWX: LONN)

›

Lonza Group (SWX: LONN) is listed on the SIX Swiss Exchange, where its shares trade in CHF. It belongs to the Diagnostics & Research industry, part of the Healthcare sector, and reports about 20,141 employees.

The shares were at 667.60 CHF on 19 November 2026, up 20.7% over 52 weeks. Its 52-week range is 454.60 CHF to 675.60 CHF: the price is 1.2% below the high and 46.9% above the low.

At a market capitalisation of 46.59B CHF, it trades at 44.2 times trailing earnings and 29.7 times forward earnings. The median trailing P/E of its 18 largest Diagnostics & Research peers is 34.9, a premium of 27% for LONN. It pays a dividend yielding 0.75% (it pays out 32% of its earnings), against a median of 0.74% among the dividend payers in that peer group.

Lonza Group reports return on equity of -3.5%, an operating margin of 23.5% and revenue up 11.2% year over year.

Its debt exceeds its cash by 3.68B CHF, a debt-to-equity ratio of 0.57. Its Piotroski F-score is 7 out of 9, a strong reading of its financial health. 23 analysts cover the stock, with an average rating of Buy; their mean price target of 719.65 CHF is 7.8% above the current price. The next earnings report is expected on 27 January 2027.